Compare NBN & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBN | COLL |
|---|---|---|
| Founded | 1872 | 2002 |
| Country | United States | United States |
| Employees | 234 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | N/A | 2015 |
| Metric | NBN | COLL |
|---|---|---|
| Price | $126.94 | $27.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $130.50 | $51.40 |
| AVG Volume (30 Days) | 87.6K | ★ 744.4K |
| Earning Date | 04-27-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.03% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $780,567,000.00 |
| Revenue This Year | $13.77 | $8.01 |
| Revenue Next Year | $18.72 | N/A |
| P/E Ratio | $11.29 | ★ N/A |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $80.75 | $25.47 |
| 52 Week High | $142.31 | $50.79 |
| Indicator | NBN | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 46.74 | 33.30 |
| Support Level | $127.84 | $25.47 |
| Resistance Level | $137.72 | $35.89 |
| Average True Range (ATR) | 2.86 | 1.18 |
| MACD | -0.60 | 0.04 |
| Stochastic Oscillator | 16.69 | 40.19 |
Northeast Bank provides banking and financial services to individual and corporate customers in the United States. The firm conducts its loan-related activities through two primary channels: the Community Banking Division, and the Small Business Administration (SBA) National Division. Its loan portfolio comprises residential mortgage loans; multi-family and other commercial real estate loans; commercial and industrial loans, consumer loans, and small business administration loans. The firm also provides telephone banking, online banking, mobile banking, and remote deposit capture services. The revenue of the company is derived principally from interest and dividends from the bank.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.